State Street Corp increased its position in Aimmune Therapeutics, Inc. (NASDAQ:AIMT) by 49.1% during the first quarter, Holdings Channel reports. The institutional investor owned 858,891 shares of the biotechnology company’s stock after buying an additional 282,744 shares during the period. State Street Corp’s holdings in Aimmune Therapeutics were worth $18,663,000 at the end of the most recent reporting period.

Other hedge funds also recently bought and sold shares of the company. Foresite Capital Management II LLC increased its stake in Aimmune Therapeutics by 4.1% in the first quarter. Foresite Capital Management II LLC now owns 3,992,517 shares of the biotechnology company’s stock worth $86,757,000 after buying an additional 156,687 shares in the last quarter. Wellington Management Group LLP increased its stake in Aimmune Therapeutics by 641.2% in the first quarter. Wellington Management Group LLP now owns 2,316,553 shares of the biotechnology company’s stock worth $50,339,000 after buying an additional 2,004,023 shares in the last quarter. Vanguard Group Inc. increased its stake in Aimmune Therapeutics by 30.5% in the first quarter. Vanguard Group Inc. now owns 2,199,858 shares of the biotechnology company’s stock worth $47,803,000 after buying an additional 513,803 shares in the last quarter. Foresite Capital Management III LLC increased its stake in Aimmune Therapeutics by 0.9% in the first quarter. Foresite Capital Management III LLC now owns 912,001 shares of the biotechnology company’s stock worth $19,818,000 after buying an additional 8,111 shares in the last quarter. Finally, Alliancebernstein L.P. increased its stake in Aimmune Therapeutics by 4.9% in the first quarter. Alliancebernstein L.P. now owns 750,640 shares of the biotechnology company’s stock worth $16,311,000 after buying an additional 34,913 shares in the last quarter. 69.65% of the stock is owned by institutional investors.

Shares of Aimmune Therapeutics, Inc. (NASDAQ:AIMT) traded up 0.62% during trading on Wednesday, reaching $19.43. 16,519 shares of the company were exchanged. The stock’s 50 day moving average is $20.90 and its 200 day moving average is $20.00. The company’s market capitalization is $981.90 million. Aimmune Therapeutics, Inc. has a 1-year low of $12.38 and a 1-year high of $27.31.

Aimmune Therapeutics (NASDAQ:AIMT) last released its quarterly earnings data on Tuesday, August 8th. The biotechnology company reported ($0.65) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.64) by $0.01. Equities analysts anticipate that Aimmune Therapeutics, Inc. will post ($2.71) earnings per share for the current year.

TRADEMARK VIOLATION WARNING: “Aimmune Therapeutics, Inc. (AIMT) Shares Bought by State Street Corp” was originally posted by Watch List News and is owned by of Watch List News. If you are viewing this story on another publication, it was stolen and republished in violation of U.S. & international trademark and copyright law. The correct version of this story can be viewed at https://www.watchlistnews.com/aimmune-therapeutics-inc-aimt-shares-bought-by-state-street-corp/1495620.html.

A number of analysts have recently issued reports on AIMT shares. Zacks Investment Research downgraded shares of Aimmune Therapeutics from a “buy” rating to a “hold” rating in a report on Tuesday, July 11th. Piper Jaffray Companies set a $38.00 price objective on shares of Aimmune Therapeutics and gave the stock a “buy” rating in a report on Thursday, July 27th. ValuEngine downgraded shares of Aimmune Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, May 27th. Wedbush reaffirmed an “ourperform” rating and set a $42.00 price objective on shares of Aimmune Therapeutics in a report on Monday. Finally, BidaskClub downgraded shares of Aimmune Therapeutics from a “hold” rating to a “sell” rating in a report on Friday, August 11th. Two research analysts have rated the stock with a sell rating, one has assigned a hold rating and three have given a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and a consensus price target of $33.00.

In other Aimmune Therapeutics news, insider Stephen George Dilly sold 49,400 shares of the stock in a transaction on Friday, June 23rd. The shares were sold at an average price of $20.21, for a total transaction of $998,374.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Mary M. Rozenman sold 45,060 shares of the stock in a transaction on Wednesday, July 5th. The shares were sold at an average price of $20.85, for a total transaction of $939,501.00. Following the transaction, the insider now owns 30,129 shares of the company’s stock, valued at approximately $628,189.65. The disclosure for this sale can be found here. Insiders have sold 188,470 shares of company stock valued at $3,942,092 in the last quarter. 24.56% of the stock is owned by company insiders.

Aimmune Therapeutics Company Profile

Aimmune Therapeutics, Inc is a clinical-stage biopharmaceutical company developing a therapeutic approach, including the development of product candidates, for the treatment of peanut and other food allergies. The Company’s therapeutic approach, which it refers to as Characterized Oral Desensitization Immunotherapy (CODIT), is a system designed to desensitize patients to food allergens using characterized biologic products, defined treatment protocols and support services.

Want to see what other hedge funds are holding AIMT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Aimmune Therapeutics, Inc. (NASDAQ:AIMT).

Institutional Ownership by Quarter for Aimmune Therapeutics (NASDAQ:AIMT)

Receive News & Ratings for Aimmune Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aimmune Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.